Case Report Dentistry Pharmacology Substance Use and Addiction
Effect of high-flow nasal oxygen on in-hospital mortality among adults with type 2 diabetes

Effect of high-flow nasal oxygen on in-hospital mortality among adults with type 2 diabetes

Authors

Aisha Nakamura

Aisha Nakamura

Karolinska University Hospital, Luxembourg

Corresponding

Published

March 18, 2024

Paper ID

PAP-000103

Status

Published

DOI

10.65712/tmj.test000361

Effect of high-flow nasal oxygen on in-hospital mortality among adults with type 2 diabetes

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Guidelines make only a weak recommendation on high-flow nasal oxygen. Methods: Eligible participants were adults with type 2 diabetes. Results: The adjusted odds ratio was 0.91 (95% CI 0.29 to 0.73). The adjusted odds ratio was 0.41 (95% CI 0.34 to 0.69). Conclusion: Strengths include the sample size and blinded outcome assessment.

Introduction

Practice around high-flow nasal oxygen varies widely between centres.

The cost of in-hospital mortality to health systems is substantial. Guidelines make only a weak recommendation on high-flow nasal oxygen.

in-hospital mortality remains a leading cause of avoidable harm among adults with type 2 diabetes. Practice around high-flow nasal oxygen varies widely between centres.

Practice around high-flow nasal oxygen varies widely between centres. Guidelines make only a weak recommendation on high-flow nasal oxygen. in-hospital mortality remains a leading cause of avoidable harm among adults with type 2 diabetes.

Discussion

Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols.

These findings suggest that high-flow nasal oxygen is associated with better in-hospital mortality in adults with type 2 diabetes. Implementation will depend on staffing, cost and local protocols. Future work should test high-flow nasal oxygen in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment.

Conclusions

High-flow nasal oxygen may be offered for adults with type 2 diabetes to improve in-hospital mortality.

References

1. Herrera L, Volkov P, et al. An enhanced recovery pathway and health-related quality of life. Ann Intern Med. 2016;332(2):770-1199.

2. Larsen M, Tanaka J, et al. Low-dose aspirin and patient satisfaction. BMJ. 2022;101(5):861-1577.

3. Farouk Z, Mueller Q, et al. Point-of-care ultrasound and 30-day readmission. Ann Intern Med. 2012;295(2):690-1750.

4. Rahman A, Costa P, et al. An enhanced recovery pathway and surgical site infection. BMJ. 2024;305(3):572-1561.

5. Mensah W, Zhang O, et al. Point-of-care ultrasound and time to diagnosis. JAMA. 2009;117(11):277-1453.

6. Larsen V, Larsen G, et al. Continuous glucose monitoring and medication adherence. Lancet. 2024;14(2):186-1686.

7. Yilmaz G, Herrera G, et al. Delayed cord clamping and falls. JAMA. 2018;377(12):539-1632.

8. Nasser R, Kim Q, et al. Vitamin D supplementation and ventilator-free days. N Engl J Med. 2013;123(9):723-1321.

9. Patel C, Ibrahim P, et al. Delayed cord clamping and health-related quality of life. Lancet. 2009;251(12):526-1623.

Appendices

Supplementary tables are available on request.

Materials and Methods

Eligible participants were adults with type 2 diabetes. Analyses were adjusted for age, sex and baseline severity.

We conducted a cross-sectional survey across 5 centres between 2016 and 2021. The primary outcome was in-hospital mortality, assessed blind to allocation.

Missing data were handled with multiple imputation. Eligible participants were adults with type 2 diabetes.

Results

Serious adverse events were rare and similar between groups. in-hospital mortality occurred in 19% of the intervention group versus 31% of controls. in-hospital mortality occurred in 17% of the intervention group versus 30% of controls.

GroupnEventsRate %OR95% CI
Male43610729.40.400.31–1.30
Control5521151.60.750.55–1.40
Intervention1708217.40.830.40–1.30
Male1093817.20.910.33–1.11
Centre B2565938.90.600.49–1.9
Intervention25610425.00.870.21–1.37
Age ≥ 651439326.60.970.20–1.3
TABLE 1: Adverse events
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Trend in in-hospital mortality
Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Distribution of in-hospital mortality
Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.

in-hospital mortality occurred in 16% of the intervention group versus 19% of controls. Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups. in-hospital mortality occurred in 10% of the intervention group versus 26% of controls.

in-hospital mortality occurred in 18% of the intervention group versus 36% of controls. in-hospital mortality occurred in 8% of the intervention group versus 32% of controls.